Q2 adj. EBIT of SEK 328m, 26% above ABGSC AUM growth of 8% q-o-q in Q2, will drive pos.
Redeye comments on Westpay’s Q2 results, which came in slightly better than expected in terms of mar...
Redeye saw a lower sales development than we expected, while Opex was in line with our estimates.
Redeye continues to see an interesting long term investment case.
Redeye updates on GiG following its Q2-report which was slightly better than expected.
Redeye provides its comments on SenzaGen’s 2022 half-year report.
Organic sales growth of 10.5% vs. ABGSCe of 5.7% Temporary gross margin pressure in H2’22e… …but opt...
Redeye retains its optimistic view on CombinedX despite lowering its Base Case and forecasts slightl...
Sales 7% above our expectations… …but adj. EBITA 23% below Management intends to ramp up M&A pace Q...
Estimate changes driven mainly by accounting changes.
Mining could commence in mid-’23 Long-term Viscaria assumptions unchanged Fair value of SEK 1.
Lower margins on installations, product margins stable Near-term cost base re-assessed Fair value SE...
Ramp-up of Pampalo progressed quite in line with our expectations.
Redeye states that the Q2 report was strong, with solid density improvements resulting in a signific...
I de senaste delårsrapporterna har Obducat uttalat, och upprepat, att ett av målen för 2022 är att ö...
AcuCorts användarvänliga kortisonfilm ISICORT® har erhållit godkännande från Läkemedelsverket i Sver...
Today, 18th of August, Fluicell released its quarterly report for the second quarter 2022.
TCECUR avslutar H1-22 med flaggan i topp där den nyligen presenterade Q2-rapporten visade stark till...
LL Lucky Games publicerade den 18 augusti sin delårsrapport för andra kvartalet 2022.
Q2 EBIT of DKK 52m in line with ABGSCe No shift to JaTak expected – cash cow set to continue New 1Y ...
